Considerations in psychotropic treatments in dementia-can polypharmacy be avoided?

International Journal of Neuropsychopharmacology

Volumn 17, Issue 7, 2014, Pages 1107-1117

  Ravona Springer, Ramit ^a   Davidson, Michael ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

Dementia; polypharmacy; psychotropic medications

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; MEMANTINE; NEUROTRANSMITTER; OLANZAPINE; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE;

AGGRESSION; APATHY; BEHAVIOR CHANGE; COGNITION; COGNITIVE DEFECT; DAYTIME SOMNOLENCE; DELIRIUM; DELUSION; DEMENTIA; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DISRUPTIVE BEHAVIOR; GERIATRIC DISORDER; HALLUCINATION; HEALTH CARE COST; HUMAN; INSOMNIA; MEDICAL EDUCATION; POLYPHARMACY; POSITIVE SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; REM SLEEP; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SLEEP DISORDER; SLEEP PATTERN; CAREGIVER; DRUG EFFECTS; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOTIC DISORDERS; SLEEP INITIATION AND MAINTENANCE DISORDERS; SOCIAL SUPPORT;

APATHY; CAREGIVERS; DEMENTIA; HUMANS; POLYPHARMACY; PSYCHOTIC DISORDERS; PSYCHOTROPIC DRUGS; SLEEP INITIATION AND MAINTENANCE DISORDERS; SOCIAL SUPPORT;

EID: 84901391150     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713000412     Document Type: Review

References (120)

1. Aharon-Peretz J, Masiah A, Pillar T, Epstein R, et al. (1991). Sleep-wake cycles in multi-infarct dementia and dementia of the Alzheimer type. Neurology 41, 1616-1619.
2. Alexander MP, Stuss DT (2000). Disorders of frontal lobe functioning. Seminars in Neurology 20, 427-437.
3. Ancoli-Israel S (2000). Insomnia in the elderly: a review for the primary care practitioner. Sleep 23 (Suppl. 1), S23-S30; discussion S36-38.
4. Ancoli-Israel S, Clopton P, Klauber MR, Fell R, et al. (1997a). Use of wrist activity for monitoring sleep/wake in demented nursing-home patients. Sleep 20, 24-27.
5. Ancoli-Israel S, Klauber MR, Jones DW, Kripke DF, et al. (1997b). Variations in circadian rhythms of activity, sleep, and light exposure related to dementia in nursing-home patients. Sleep 20, 18-23.
6. Ballard C, Waite J (2006). The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Systematic Reviews CD003476.
7. Ballard CG, Gauthier S, Cummings JL, Brodaty H, et al. (2009). Management of agitation and aggression associated with Alzheimer's disease. Nature Reviews Neurology 5, 245-255.
8. Ballard CG, Margallo-Lana M, Fossey J, Reichelt K, et al. (2001). A 1-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments. Journal of Clinical Psychiatry 62, 631-636.
9. Barnhart WJ, Makela EH, Latocha MJ (2004). SSRI-induced apathy syndrome: a clinical review. Journal of Psychiatric Practice 10, 196-199.
10. Bartlett G, Abrahamowicz M, Tamblyn R, Grad R, et al. (2004). Longitudinal patterns of new Benzodiazepine use in the elderly. Pharmacoepidemiology and Drug Safety 13, 669-682.
11. Basu R, Dodge H, Stoehr GP, Ganguli M (2003). Sedative-hypnotic use of diphenhydramine in a rural, older adult, community-based cohort: effects on cognition. American Journal of Geriatric Psychiatry 11, 205-213.
12. Berman K, Brodaty H, Withall A, Seeher K (2012). Pharmacologic treatment of apathy in dementia. American Journal of Geriatric Psychiatry 20, 104-122.
13. Bliwise DL (2004). Sleep disorders in Alzheimer's disease and other dementias. Clinical Cornerstone 6 (Suppl. 1A), S16-S28.
14. Boeve BF, Silber MH, Ferman TJ, Lucas JA, et al. (2001). Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Movement Disorders 16, 622-630.
15. Borroni B, Costanzi C, Padovani A (2010). Genetic susceptibility to behavioural and psychological symptoms in Alzheimer disease. Current Alzheimer Research 7, 158-164.
16. Borroni B, Grassi M, Agosti C, Archetti S, et al. (2006). Cumulative effect of COMT and 5-HTTLPR polymorphisms and their interaction with disease severity and comorbidities on the risk of psychosis in Alzheimer's disease. American Journal of Geriatric Psychiatry 14, 343-351.
17. Campbell P, Wright J, Oyebode J, Job D, et al. (2008). Determinants of burden in those who care for someone with dementia. International Journal of Geriatric Psychiatry 23, 1078-1085.
18. Clark LK, Warman D, Lysaker PH (2010). The relationships between schizophrenia symptom dimensions and executive functioning components. Schizophrenia Research 124, 169-175.
19. Cohen-Mansfield J (2008). Agitated behavior in persons with dementia: the relationship between type of behavior, its frequency, and its disruptiveness. Journal of Psychiatric Research 43, 64-69.
20. Cohen-Mansfield J, Golander H, Ben-Israel J, Garfinkel D (2011). The meanings of delusions in dementia: a preliminary study. Psychiatry Research 189, 97-104.
21. Collins LG, Swartz K (2011). Caregiver care. American Family Physician 83, 1309-1317.
22. Cornege-Blokland E, Kleijer BC, HertoghCM, vanMarumRJ (2010). Reasons to prescribe antipsychotics for the behavioral symptoms of dementia: a survey in Dutch nursing homes among physicians, nurses, and family caregivers. Journal of American Medical Directors Association 13, 80e1-80e6.
23. Craig D, Mirakhur A, Hart DJ, McIlroy SP, et al. (2005). A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer's disease. American Journal of Geriatric Psychiatry 13, 460-468.
24. Desplenter F, Caenen C, Meelberghs J, Hartikainen S, et al. (2011). Change in psychotropic drug use among community-dwelling people aged 75 years and older in Finland: repeated cross-sectional population studies. International Psychogeriatrics 23, 1278-1284.
25. de Vugt ME, Stevens F, Aalten P, Lousberg R, et al. (2005). A prospective study of the effects of behavioral symptoms on the institutionalization of patients with dementia. International Psychogeriatrics 17, 577-589.
26. Dolder CR, Davis LN, McKinsey J (2010). Use of psychostimulants in patients with dementia. Annals of Pharmacotherapy 44, 1624-1632.
27. Dorsey ER, Rabbani A, Gallagher SA, Conti RM, et al. (2010). Impact of FDA black box advisory on antipsychotic medication use. Archives of Internal Medicine 170, 96-103.
28. Dubois B, McKeith I, Orgogozo JM, Collins O, et al. (1999). A multicentre, randomized, double-blind, placebocontrolled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study. International Journal of Geriatric Psychiatry 14, 973-982.
29. Dwyer LL, Han B, Woodwell DA, Rechtsteiner EA (2010). Polypharmacy in nursing home residents in the United States: results of the 2004 National Nursing Home Survey. American Journal of Geriatric Pharmacotherapy 8, 63-72.
30. Enache D, Winblad B, Aarsland D (2011). Depression in dementia: epidemiology, mechanisms, and treatment. Current Opinion in Psychiatry 24, 461-472.
31. Etters L, Goodall D, Harrison BE (2008). Caregiver burden among dementia patient caregivers: a review of the literature. Journal of American Academy of Nurse Practitioners 20, 423-428.
32. Fick D, Kolanowski A, Waller J (2007). High prevalence of central nervous system medications in community-dwelling older adults with dementia over a three-year period. Aging and Mental Health 11, 588-595.
33. Foley DJ, Monjan AA, Brown SL, Simonsick EM, et al. (1995). Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep 18, 425-432.
34. Forstl H, Besthorn C, Burns A, Geiger-Kabisch C, et al. (1994). Delusional misidentification in Alzheimer's disease: a summary of clinical and biological aspects. Psychopathology 27, 194-199.
35. Gallagher-Thompson D, Brooks JO III, Bliwise D, Leader J, et al. (1992). The relations among caregiver stress, 'sundowning' symptoms, and cognitive decline in Alzheimer's disease. Journal of the American Geriatric Society 40, 807-810.
36. Guthrie B, Clark SA, McCowan C (2010). The burden of psychotropic drug prescribing in people with dementia: a population database study. Age and Ageing 39, 637-642.
37. Halter JB, Ouslander JG, Tinetti ME, Studenski S, High KP, Asthana S (2009). Hazzard's geriatric medicine and Gerontology, 6e. New York: McGraw-Hill.
38. Hartikainen S, Mantyselka P, Louhivuori-Laako K, Enlund H, et al. (2005). Concomitant use of analgesics and psychotropics in home-dwelling elderly people-Kuopio 75+study. British Journal of Clinical Pharmacology 60, 306-310.
39. Herrmann N, Mamdani M, Lanctot KL (2004). Atypical antipsychotics and risk of cerebrovascular accidents. American Journal of Psychiatry 161, 1113-1115.
40. Herrmann N, Rothenburg LS, Black SE, Ryan M, et al. (2008). Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. Journal of Clinical Psychopharmacology 28, 296-301.
41. Howes OD, Egerton A, Allan V, McGuire P, et al. (2009). Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Current Pharmaceutical Design 15, 2550-2559.
42. Huang SS, Lee MC, Liao YC, Wang WF, et al. (2011). Caregiver burden associated with behavioral and psychological symptoms of dementia (BPSD) in Taiwanese elderly. Archives Gerontology and Geriatrics 55, 55-59.
43. Isacson D (1997). Long-term benzodiazepine use: factors of importance and the development of individual use patterns over time-a 13-year follow-up in a Swedish community. Social Science and Medicine 44, 1871-1880.
44. Ishii S, Streim JE, Saliba D (2010). Potentially reversible resident factors associated with rejection of care behaviors. Journal of the American Geriatrics Society 58, 1693-1700.
45. Ismail Z, Nguyen MQ, Fischer CE, Schweizer TA, et al. (2011). Neurobiology of delusions in Alzheimer's disease. Current Psychiatry Reports 13, 211-218.
46. Jyrkka J, Enlund H, Korhonen MJ, Sulkava R, et al. (2009). Patterns of drug use and factors associated with polypharmacy and excessive polypharmacy in elderly persons: results of the Kuopio 75+ study: a cross-sectional analysis. Drugs and Aging 26, 493-503.
47. Kang JY, Lee JS, Kang H, Lee HW, et al. (2011). Regional cerebral blood flow abnormalities associated with apathy and depression in Alzheimer's disease. Alzheimer Disease and Associated Disorders 26, 217-224.
48. Kaplitz SE (1975). Withdrawn, apathetic geriatric patients responsive to methylphenidate. Journal of the American Geriatrics Society 23, 271-276.
49. Kapur S (2003). Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. American Journal of Psychiatry 160, 13-23.
50. Kennerfalk A, Ruigomez A, Wallander MA, Wilhelmsen L, et al. (2002). Geriatric drug therapy and healthcare utilization in the United Kingdom. Annals of Pharmacotherapy 36, 797-803.
51. Kim Y, Schulz R (2008). Family caregiver's strains: comparative analysis of cancer caregiving with dementia, diabetes, and frail elderly caregiving. Journal of Aging and Health 20, 483-503.
52. Lai SW, Lin CH, Liao KF, Su LT, Sung FC, Lin CC (2012). Association between polypharmacy and dementia in older people: a population-based case-control study in Taiwan. Geriatr Gerontol Int 12, 491-498.
53. Laredo L, Vargas E, Blasco AJ, Aguilar MD, et al. (2011). Risk of cerebrovascular accident associated with use of antipsychotics: population-based case-control study. Journal of the American Geriatrics Society 59, 1182-1187.
54. Lee E, Akanuma K, Meguro M, Ishii H, et al. (2007). Confabulations in remembering past and planning future are associated with psychiatric symptoms in Alzheimer's disease. Archives of Clinical Neuropsychology 22, 949-956.
55. Lee E, Kinomura S, Meguro K, Akanuma K, et al. (2009). Confabulations on episodic and semantic memory questions are associated with different neurologic backgrounds in Alzheimer disease. Cognitive and Behavioral Neurology 22, 81-88.
56. Leonard R, Tinetti ME, Allore HG, Drickamer MA (2006). Potentially modifiable resident characteristics that are associated with physical or verbal aggression among nursing home residents with dementia. Archives of Internal Medicine 166, 1295-1300.
57. Levy R, Dubois B (2006). Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cerebral Cortex 16, 916-928.
58. Lin RY, Heacock LC, Fogel JF (2010). Drug-induced, dementia-associated and non-dementia, non-drug delirium hospitalizations in the United States, 1998-2005: an analysis of the national inpatient sample. Drugs and Aging 27, 51-61.
59. Liperoti R, Gambassi G, Lapane KL, Chiang C, et al. (2005). Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. Journal of Clinical Psychiatry 66, 1090-1096.
60. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, et al. (2002). Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. Journal of the American Medical Association 288, 1475-1483.
61. McCurry SM, Logsdon RG, Teri L, Gibbons LE, et al. (1999). Characteristics of sleep disturbance in community-dwelling Alzheimer's disease patients. Journal of Geriatric Psychiatry and Neurology 12, 53-59.
62. McGaffigan S, Bliwise DL (1997). The treatment of sundowning. A selective review of pharmacological and nonpharmacological studies. Drugs and Aging 10, 10-17.
63. McKeith I, Del Ser T, Spano P, EmreM, et al. (2000). Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356, 2031-2036.
64. Maher AR, Maglione M, Bagley S, Suttorp M, et al. (2011). Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. Journal of the American Medical Association 306, 1359-1369.
65. Marin RS (1991). Apathy: a neuropsychiatric syndrome. Journal of Neuropsychiatry and Clinical Neurosciences 3, 243-254.
66. Mausbach BT, von Kanel R, Aschbacher K, Roepke SK, et al. (2007). Spousal caregivers of patients with Alzheimer's disease show longitudinal increases in plasma level of tissue-type plasminogen activator antigen. Psychosomatic Medicine 69, 816-822.
67. Mendez MF, Fras IA, Kremen SA, Tsai PH (2011). False reports from patients with frontotemporal dementia: delusions or confabulations? Behavioural Neurology 24, 237-244.
68. Mishima K, Tozawa T, Satoh K, Matsumoto Y, et al. (1999). Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer's type with disturbed sleep-waking. Biological Psychiatry 45, 417-421.
69. Mizrahi R, Starkstein SE (2007). Epidemiology and management of apathy in patients with Alzheimer's disease. Drugs and Aging 24, 547-554.
70. Mohamed S, Rosenheck R, Lyketsos CG, Schneider LS (2010). Caregiver burden in Alzheimer disease: crosssectional and longitudinal patient correlates. American Journal of Geriatric Psychiatry 18, 917-927.
71. Molyneux GJ, McCarthy GM, McEniff S, Cryan M, et al. (2008). Prevalence and predictors of carer burden and depression in carers of patients referred to an old age psychiatric service. International Psychogeriatrics 20, 1193-1202.
72. Mulin E, Leone E, Dujardin K, Delliaux M, et al. (2011). Diagnostic criteria for apathy in clinical practice. International Journal of Geriatric Psychiatry 26, 158-165.
73. Neikrug AB, Ancoli-Israel S (2010). Sleep disorders in the older adult-a mini-review. Gerontology 56, 181-189.
74. Nelson JC, Devanand DP (2011). A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. Journal of the American Geriatrics Society 59, 577-585.
75. Ohayon MM, Carskadon MA, Guilleminault C, VitielloMV (2004). Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan. Sleep 27, 1255-1273.
76. Olin JT, Schneider LS, Katz IR, Meyers BS, et al. (2002). Provisional diagnostic criteria for depression of Alzheimer disease. American Journal of Geriatric Psychiatry 10, 125-128.
77. Onder G, Liperoti R, Fialova D, Topinkova E, et al. (2012). Polypharmacy in Nursing Home in Europe: results from the SHELTER Study. Journal of Gerontology A: Biological Sciences and Medical Sciences 67, 698-704.
78. Ownby RL, Saeed M, Wohlgemuth W, Capasso R, et al. (2010). Caregiver reports of sleep problems in non-Hispanic white, Hispanic, and African American patients with Alzheimer dementia. Journal of Clinical Sleep Medicine 6, 281-289.
79. Padala PR, Burke WJ, Shostrom VK, Bhatia SC, et al. (2010). Methylphenidate for apathy and functional status in dementia of the Alzheimer type. American Journal of Geriatric Psychiatry 18, 371-374.
80. Perez-Madrinan G, Cook SE, Saxton JA, Miyahara S, et al. (2004). Alzheimer disease with psychosis: excess cognitive impairment is restricted to the misidentification subtype. American Journal of Geriatric Psychiatry 12, 449-456.
81. Pollak CP, Perlick D, Linsner JP, Wenston J, et al. (1990). Sleep problems in the community elderly as predictors of death and nursing home placement. Journal of Community Health 15, 123-135.
82. Prinz PN, Peskind ER, Vitaliano PP, Raskind MA, et al. (1982). Changes in the sleep and waking EEGs of nondemented and demented elderly subjects. Journal of the American Geriatrics Society 30, 86-93.
83. Ramanathan S, Glatt SJ (2009). Serotonergic system genes in psychosis of Alzheimer dementia: meta-analysis. American Journal of Geriatric Psychiatry 17, 839-846.
84. Raskind MA, Cyrus PA, Ruzicka BB, Gulanski BI (1999). The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group. Journal of Clinical Psychiatry 60, 318-325.
85. Reeves S, Brown R, Howard R, Grasby P (2009). Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer disease. Neurology 72, 528-534.
86. Reynolds CF III, Kupfer DJ, Taska LS, Hoch CC, et al. (1985). Sleep apnea in Alzheimer's dementia: correlation with mental deterioration. Journal of Clinical Psychiatry 46, 257-261.
87. Riedel M, Strassnig M, Muller N, Zwack P, et al. (2005). How representative of everyday clinical populations are schizophrenia patients enrolled in clinical trials? European Archives of Psychiatry and Clinical Neuroscience 255, 143-148.
88. Rikala M, Korhonen MJ, Sulkava R, Hartikainen S (2011a). The effects of medication assessment on psychotropic drug use in the community-dwelling elderly. International Psychogeriatrics 23, 473-484.
89. Rikala M, Korhonen MJ, Sulkava R, Hartikainen S (2011b). Psychotropic drug use in community-dwelling elderly people-characteristics of persistent and incident users. European Journal of Clinical Pharmacology 67, 731-739.
90. Rosenheck RA, Leslie DL, Sindelar JL, Miller EA, et al. (2007). Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. Archives of General Psychiatry 64, 1259-1268.
91. Rosness TA, Mjorud M, Engedal K (2011). Quality of life and depression in carers of patients with early onset dementia. Aging and Mental Health 15, 299-306.
92. Rowe MA, Kelly A, Horne C, Lane S, et al. (2009). Reducing dangerous nighttime events in persons with dementia by using a nighttime monitoring system. Alzheimer's and Dementias 5, 419-426.
93. Salami O, Lyketsos C, Rao V (2011). Treatment of sleep disturbance in Alzheimer's dementia. International Journal of Geriatric Psychiatry 26, 771-782.
94. Sanders RD (2011). Hypothesis for the pathophysiology of delirium: role of baseline brain network connectivity and changes in inhibitory tone. Medical Hypotheses 77, 140-143.
95. Schneider LS, Dagerman K, Insel PS (2006a). Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. American Journal of Geriatric Psychiatry 14, 191-210.
96. Schneider LS, Tariot PN, Dagerman KS, Davis SM, et al. (2006b). Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. New England Journal of Medicine 355, 1525-1538.
97. Schulz R, Beach SR (1999). Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. Journal of the American Medical Association 282, 2215-2219.
98. Seitz DP, Adunuri N, Gill SS, Gruneir A, et al. (2011). Antidepressants for agitation and psychosis in dementia. Cochrane Database of Systematic Reviews CD008191.
99. Shorr RI, Griffin MR, Daugherty JR, Ray WA (1992). Opioid analgesics and the risk of hip fracture in the elderly: codeine and propoxyphene. Journal of Gerontology 47, M111-M115.
100. Shub D, Darvishi R, Kunik ME (2009). Non-pharmacologic treatment of insomnia in persons with dementia. Geriatrics 64, 22-26.
101. Sultzer DL, Davis SM, Tariot PN, Dagerman KS, et al. (2008). Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. American Journal of Psychiatry 165, 844-854.
102. Tagariello P, Girardi P, Amore M (2009). Depression and apathy in dementia: same syndrome or different constructs? A critical review. Archives Gerontology Geriatrics 49, 246-249.
103. Tan LL, Wong HB, Allen H (2005). The impact of neuropsychiatric symptoms of dementia on distress in family and professional caregivers in Singapore. International Psychogeriatrics 17, 253-263.
104. Tariot PN, Cummings JL, Katz IR, Mintzer J, et al. (2001). A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society 49, 1590-1599.
105. Tew CW, Tan LF, Luo N, Ng WY, et al. (2010). Why family caregivers choose to institutionalize a loved one with dementia: a Singapore perspective. Dementia and Geriatric Cognitive Disorders 30, 509-516.
106. Tsunoda K, Uchida H, Suzuki T, Watanabe K, et al. (2010). Effects of discontinuing benzodiazepine-derivative hypnotics on postural sway and cognitive functions in the elderly. International Journal of Geriatric Psychiatry 25, 1259-1265.
107. Uchida H, Suzuki T, Mamo DC, Mulsant BH, et al. (2008). Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: a survey of 1418 patients in Japan. American Journal of Geriatric Psychiatry 16, 584-593.
108. Vigen CL, Mack WJ, Keefe RS, Sano M, et al. (2011). Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. American Journal of Psychiatry 168, 831-839.
109. Vitaliano PP, Murphy M, Young HM, Echeverria D, et al. (2011). Does caring for a spouse with dementia promote cognitive decline? A hypothesis and proposed mechanisms. Journal of the American Geriatrics Society 59, 900-908.
110. Vitiello MV, Borson S (2001). Sleep disturbances in patients with Alzheimer's disease: epidemiology, pathophysiology and treatment. CNS Drugs 15, 777-796.
111. Volicer L, Van der Steen JT, Frijters DH (2009). Modifiable factors related to abusive behaviors in nursing home residents with dementia. Journal of the American Medical Directors Association 10, 617-622.
112. Waite A, Bebbington P, Skelton-Robinson M, Orrell M (2004). Social factors and depression in carers of people with dementia. International Journal of Geriatric Psychiatry 19, 582-587.
113. Wetzels RB, Zuidema SU, de Jonghe JF, Verhey FR, et al. (2010). Course of neuropsychiatric symptoms in residents with dementia in nursing homes over 2-year period. American Journal of Geriatric Psychiatry 18, 1054-1065.
114. Wiegand MH (2008). Antidepressants for the treatment of insomnia: a suitable approach? Drugs 68, 2411-2417.
115. Winblad B, Poritis N (1999). Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). International Journal of Geriatric Psychiatry 14, 135-146.
116. Wongpakaran N, van Reekum R, Wongpakaran T, Clarke D (2007). Selective serotonin reuptake inhibitor use associates with apathy among depressed elderly: a case-control study. Annals of General Psychiatry 6, 7.
117. Wu YH, Swaab DF (2007). Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease. Sleep Medicine 8, 623-636.
118. Youn JC, Lee DY, Jhoo JH, Kim KW, et al. (2011). Prevalence of neuropsychiatric syndromes in Alzheimer's disease (AD). Archives of Gerontology and Geriatrics 52, 258-263.
119. Yury CA, Fisher JE (2007). Meta-analysis of the effectiveness of atypical antipsychotics for the treatment of behavioural problems in persons with dementia. Psychotherapy and Psychosomatics 76, 213-218.
120. Ziere G, Dieleman JP, Hofman A, Pols HA, et al. (2006). Polypharmacy and falls in the middle age and elderly population. British Journal of Clinical Pharmacology 61, 218-223.